Vertex Pharmaceuticals Inc. diskutieren
Vertex Pharmaceuticals Inc.
WKN: 882807 / Symbol: VRTX / Name: Vertex / Aktie / Biotechnologie & medizinische Forschung / Large Cap /
425,25 €
-0,40 %
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at Evercore ISI from an "in-line" rating to an "outperform" rating. They now have a $438.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at HC Wainwright from $457.00 to $462.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Piper Sandler from $450.00 to $456.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $462.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at BMO Capital Markets from $480.00 to $500.00. They now have an "outperform" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Argus from $465.00 to $550.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Wells Fargo & Company from $540.00 to $555.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $545.00 price target on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was upgraded by analysts at StockNews.com from a "buy" rating to a "strong-buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Cantor Fitzgerald from $440.00 to $480.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at TD Cowen from $450.00 to $500.00. They now have a "buy" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) was downgraded by analysts at StockNews.com from a "strong-buy" rating to a "buy" rating.
Ratings data for VRTX provided by MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) had its price target raised by analysts at Piper Sandler from $500.00 to $535.00. They now have an "overweight" rating on the stock.
Ratings data for VRTX provided by MarketBeat
Neueste Beiträge
Royal_Bank_of_Canada in Agnico Eagle Mines Ltd diskutieren